Search Results

OBI Pharma, a clinical-stage oncology company, announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate targeting TROP2, an antigen overexpressed in multiple tumor types.

OBI Pharma, Inc. announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate.

OBI Pharma, a clinical stage oncology company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody - drug conjugate cancer therapy targeting TROP2.

The Partner of Biosion Inc., OBI Pharma, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for OBI-992, to conduct a Phase 1/2 study of its novel antibody drug conjugate cancer therapy targeting TROP2.

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally.

OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.

OBI Pharma, Inc., a Taiwan biopharma company, and Odeon Therapeutics, a China biopharma company, have entered into an exclusive license agreement whereby OBI grants rights of OBI-999, a novel antibody-drug conjugate, and OBI-833, a therapeutic cancer vaccine, targeting the tumor antigen Globo H in China, Hong Kong and Macau to Odeon.

OBI Pharma, a Taiwan biopharma company, announced that the first patients have been enrolled in both of the Phase 2 studies of OBI-999, an antibody drug conjugate cancer therapy targeting Globo H, and OBI-3424, a prodrug targeting the enzyme aldo-keto reductase 1C3.

OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced discontinuation of the Phase 1/2 Study* for OBI 888, a Globo H antibody, upon completion of enrollment in our investigative sites.